Invesco Nasdaq Biotechnology Etf Profile

IBBQ Etf  USD 23.20  0.19  0.83%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 9

 
High
 
Low
Low
Invesco Nasdaq is selling at 23.20 as of the 28th of November 2024; that is 0.83 percent increase since the beginning of the trading day. The etf's last reported lowest price was 23.08. Invesco Nasdaq has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Invesco Nasdaq Biotechnology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
The fund generally will invest at least 90 percent of its total assets in the securities that comprise the index. Invesco Nasdaq is traded on NASDAQ Exchange in the United States. More on Invesco Nasdaq Biotechnology

Moving together with Invesco Etf

  0.8XLV Health Care SelectPairCorr
  0.85VHT Vanguard Health CarePairCorr
  0.98IBB iShares Biotechnology ETFPairCorr
  0.9XBI SPDR SP BiotechPairCorr
  0.77IXJ iShares Global HealthcarePairCorr

Moving against Invesco Etf

  0.48VO Vanguard Mid CapPairCorr
  0.42VUG Vanguard Growth IndexPairCorr
  0.41VB Vanguard Small CapPairCorr
  0.4VTI Vanguard Total StockPairCorr
  0.39SPY SPDR SP 500 Aggressive PushPairCorr
  0.39IVV iShares Core SPPairCorr

Invesco Etf Highlights

Thematic Ideas
(View all Themes)
Business ConcentrationSector ETFs, Health Care ETFs, Health, Invesco (View all Sectors)
IssuerInvesco
Inception Date2021-06-11
BenchmarkNasdaq Biotechnology Index
Entity TypeRegulated Investment Company
Asset Under Management40.7 Million
Asset TypeEquity
CategorySector
FocusHealth Care
Market ConcentrationDeveloped Markets
RegionNorth America
AdministratorThe Bank of New York Mellon Corporation
AdvisorInvesco Capital Management LLC
CustodianThe Bank of New York Mellon Corporation
DistributorInvesco Distributors, Inc
Portfolio ManagerPeter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser
Transfer AgentThe Bank of New York Mellon Corporation
Fiscal Year End31-Aug
ExchangeNASDAQ
Number of Constituents214
Market MakerLatour Trading
Total Expense0.19
Management Fee0.19
Country NameUSA
Returns Y T D5.95
NameInvesco Nasdaq Biotechnology ETF
Currency CodeUSD
Open FigiBBG011B9TYG1
In Threey Volatility17.47
1y Volatility17.35
200 Day M A22.8843
50 Day M A23.5694
CodeIBBQ
Updated At27th of November 2024
Currency NameUS Dollar
In Threey Sharp Ratio(0.23)
Invesco Nasdaq Biotechnology [IBBQ] is traded in USA and was established 2021-06-09. The fund is listed under Health category and is part of Invesco family. The entity is thematically classified as Sector ETFs. Invesco Nasdaq Biote currently have 19.84 M in assets under management (AUM). , while the total return for the last 3 years was -0.7%.
Check Invesco Nasdaq Probability Of Bankruptcy

Geographic Allocation (%)

Top Invesco Nasdaq Biotechnology Etf Constituents

KROSKeros TherapeuticsStockHealth Care
BBIOBridgeBio PharmaStockHealth Care
VIRVir BiotechnologyStockHealth Care
ETNB89bio IncStockHealth Care
LXRXLexicon PharmaceuticalsStockHealth Care
ITCIIntracellular ThStockHealth Care
TWSTTwist Bioscience CorpStockHealth Care
TVTXTravere TherapeuticsStockHealth Care
More Details

Invesco Nasdaq Biote Risk Profiles

The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Invesco Nasdaq. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.

Invesco Nasdaq Against Markets

When determining whether Invesco Nasdaq Biote is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Invesco Etf is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Invesco Nasdaq Biotechnology Etf. Highlighted below are key reports to facilitate an investment decision about Invesco Nasdaq Biotechnology Etf:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Invesco Nasdaq Biotechnology. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
The market value of Invesco Nasdaq Biote is measured differently than its book value, which is the value of Invesco that is recorded on the company's balance sheet. Investors also form their own opinion of Invesco Nasdaq's value that differs from its market value or its book value, called intrinsic value, which is Invesco Nasdaq's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Invesco Nasdaq's market value can be influenced by many factors that don't directly affect Invesco Nasdaq's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Invesco Nasdaq's value and its price as these two are different measures arrived at by different means. Investors typically determine if Invesco Nasdaq is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Invesco Nasdaq's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.